The past, present and perhaps future of pharmacovigilance: Homage to Folke Sjoqvist

European Journal of Clinical Pharmacology

Volumn 69, Issue SUPPL. 1, 2013, Pages

  Moore, Nicholas ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Adverse drug reactions; Drug prescribing behaviour; Drug user behaviour; Pharmacovigilance; Real life risk assessment

Indexed keywords

BENFLUOREX; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; DRUG;

ARTICLE; DATA MINING; DRUG EFFICACY; DRUG FORMULARY; DRUG INDUSTRY; DRUG INFORMATION; DRUG PACKAGING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; HEALTH CARE PERSONNEL; HUMAN; INSTRUMENTAL VARIABLE ANALYSIS; INTERNET; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROPENSITY SCORE; REFERENCE DATABASE; RISK MANAGEMENT; SOCIAL MEDIA; UNCERTAINTY; FORECASTING;

FORECASTING; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOVIGILANCE;

EID: 84886735430     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1486-8     Document Type: Article

References (117)

1. McBride WG (1961) Thalidomide and congenital abnormalities. Lancet 2:1358
2. Lagier G, Efthymiou ML, Lechat P, Fournier E (1974) Pharmacovigilance in the hospital. First results. Therapie 29(6):805-810
3. Dunlop D (1974) Pharmacovigilance in the framework of recording and control of drugs in the United Kingdom. Therapie 29(6):799-804
4. Wilson AB (1977) Post-marketing surveillance of adverse reactions to new medicines. Br Med J 2(6093):1001-1003
5. Fox N (1976) Adverse drug reaction monitoring program. Can J Hosp Pharm 29(5):146-164
6. Lee B, Turner WM (1978) Food and drug administration's adverse drug reaction monitoring program. Am J Hosp Pharm 35(8):929-932
7. Moore N, Biour M, Paux G, Loupi E, Begaud B, Boismare F, Royer RJ (1985) Adverse drug reaction monitoring: doing it the French way. Lancet 2(8463):1056-1058
8. Faich GA (1986) Adverse-drug-reaction monitoring. N Engl J Med 314(24):1589-1592. doi:10.1056/NEJM198606123142427
9. Meyboom R, Royer RJ (1992) Causality classification in pharmacovigilance centres in the European Community. Pharmacoepidemiol Drug Saf 10(2):93-102
10. Pere JC, Begaud B, Haramburu F, Albin H (1986) Computerized comparison of six adverse drug reaction assessment procedures. Clin Pharmacol Ther 40(4):451-461
11. Macedo AF, Marques FB, Ribeiro CF, Teixeira F (2003) Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel, according to different levels of imputability. J Clin Pharm Ther 28(2):137-143
12. Theophile H, Arimone Y, Miremont-Salame G, Moore N, Fourrier-Reglat A, Haramburu F, Begaud B (2010) Comparison of three methods (consensual expert judgement, algorithmic and probabilistic approaches) of causality assessment of adverse drug reactions: an assessment using reports made to a French pharmacovigilance centre. Drug Saf 33(11):1045-1054. doi:10.2165/11537780- 000000000-00000
13. Jones JK (1987) A Bayesian approach to causality assessment. Psychopharmacol Bull 23(3):395-399
14. Theophile H, Andre M, Arimone Y, Haramburu F, Miremont-Salame G, Begaud B (2012) An updated method improved the assessment of adverse drug reaction in routine pharmacovigilance. J Clin Epidemiol 65(10):1069-1077. doi:10.1016/j.jclinepi.2012.04.015
15. Arimone Y, Begaud B, Miremont-Salame G, Fourrier-Reglat A, Molimard M, Moore N, Haramburu F (2006) A new method for assessing drug causation provided agreement with experts' judgment. J Clin Epidemiol 59(3):308-314
16. Begaud B, Evreux JC, Jouglard J, Lagier G (1985) Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 40(2):111-118
17. Edwards IR, Biriell C (1994) Harmonisation in pharmacovigilance. Drug Saf Int J Med Toxicol Drug Exp 10(2):93-102
18. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239-245
19. Begaud B, Moride Y, Tubert-Bitter P, Chaslerie A, Haramburu F (1994) False-positives in spontaneous reporting: should we worry about them? Br J Clin Pharmacol 38(5):401-404
20. Tubert P, Begaud B, Haramburu F, Pere JC (1991) Spontaneous reporting: how many cases are required to trigger a warning? Br J Clin Pharmacol 32(4):407-408
21. Abou Chakra CN, Pariente A, Pinet M, Nkeng L, Moore N, Moride Y (2010) Case series in drug safety: a review to determine characteristics and quality. Drug Saf 33(12):1081-1088. doi:10.2165/11539300-000000000-00000
22. Tubert P, Begaud B, Pere JC, Haramburu F, Lellouch J (1992) Power and weakness of spontaneous reporting: a probabilistic approach. J Clin Epidemiol 45(3):283-286
23. Tubert P, Begaud B (1991) Random models for margins of a 2x2 contingency table and application to pharmacovigilance. Stat Med 10(6):991-999
24. Tubert-Bitter P, Begaud B, Moride Y, Chaslerie A, Haramburu F (1996) Comparing the toxicity of two drugs in the framework of spontaneous reporting: a confidence interval approach. J Clin Epidemiol 49(1):121-123
25. Pierfitte C, Begaud B, Lagnaoui R, Moore ND (1999) Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol 47(3):329-331
26. Moride Y, Haramburu F, Requejo AA, Begaud B (1997) Underreporting of adverse drug reactions in general practice. Br J Clin Pharmacol 43(2):177-181
27. Begaud B, Martin K, Haramburu F, Moore N (2002) Rates of spontaneous reporting of adverse drug reactions in France. JAMA 288(13):1588
28. Alvarez-Requejo A, Carvajal A, Begaud B, Moride Y, Vega T, Arias LH (1998) Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol 54(6):483-488
29. Theophile H, Laporte JR, Moore N, Martin KL, Begaud B (2011) The case-population study design: an analysis of its application in pharmacovigilance. Drug Saf 34(10):861-868. doi:10.2165/11592140-000000000- 000006
30. Moore N, Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jove J, Pariente A, Blin P, Benichou J, Begaud B (2013) Choice of the denominator in case population studies: event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France. Pharmacoepidemiol Drug Saf 22(2):160-167. doi:10.1002/pds.3371
31. Gulmez SE, Larrey D, Pageaux GP, Lignot-Maleyran S, de Vries C, Sturkenboom M, Perez-Gutthann S, Benichou J, Bissoli F, Horsmans Y, Bernuau J, Stricker B, Thorburn D, Blin P, Moore N (2013) Methodology for a multinational case-population study on liver toxicity risks with NSAIDs: the Study of Acute Liver Transplant (SALT). Eur J Clin Pharmacol 69(3):605-616. doi:10.1007/s00228-012-1357-8
32. Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jove J, Gatta A, McCormick PA, Metselaar HJ, Monteiro E, Thorburn D, Bernal W, Zouboulis-Vafiadis I, de Vries C, Perez-Gutthann S, Sturkenboom M, Benichou J, Montastruc JL, Horsmans Y, Salvo F, Hamoud F, Micon S, Droz-Perroteau C, Blin P, Moore N (2013) Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (Acetaminophen): The Multinational Case-Population SALT Study. Drug Saf. doi:10.1007/s40264-012-0013-7
33. Capella D, Pedros C, Vidal X, Laporte JR (2002) Case-population studies in pharmacoepidemiology. Drug Saf Int J Med Toxicol Drug Exp 25(1):7-19
34. Capella D, Laporte JR, Vidal X, Wiholm BE, Begaud B, Langman MJ, Rawlings M (1998) European network for the case-population surveillance of rare diseases (Euronet). A prospective feasibility study. Eur J Clin Pharmacol 53(5):299-302
35. Ibanez L, Ballarin E, Vidal X, Laporte JR (2000) Agranulocytosis associated with calcium dobesilate clinical course and risk estimation with the case-control and the case-population approaches. Eur J Clin Pharmacol 56(9-10):763-767
36. Stricker BH, Tijssen JG (1992) Serum sickness-like reactions to cefaclor. J Clin Epidemiol 45(10):1177-1184
37. Moore N, Noblet C, Joannides R, Ollagnier M, Imbs JL, Lagier G (1993) Cough and ACE inhibitors [letter]. Lancet 341(8836):61
38. Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, Ollagnier M, Begaud B (1997) Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database [see comments]. Br J Clin Pharmacol 44(5):513-518
39. Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13(8):519-523. doi:10.1002/pds.1001
40. Moore N, Thiessard F, Begaud B (2005) The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf 14(4):285-286
41. Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483-486. doi:10.1002/pds.677
42. Waller P, van Puijenbroek E, Egberts A, Evans S (2004) The reporting odds ratio versus the proportional reporting ratio: 'deuce'. Pharmacoepidemiol Drug Saf 13(8):525-526. doi:10.1002/pds.1002, discussion 527-528
43. Bate A, Lindquist M, Edwards IR, Orre R (2002) A data mining approach for signal detection and analysis. Drug Saf Int J Med Toxicol Drug Exp 25(6):393-397
44. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54(4):315-321
45. Bate A (2007) Bayesian confidence propagation neural network. Drug Saf Int J Med Toxicol Drug Exp 30(7):623-625
46. Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N (2007) Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 82(2):157-166. doi:10.1038/sj.clpt.6100258
47. Almenoff JS, LaCroix KK, Yuen NA, Fram D, DuMouchel W (2006) Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department. Drug Saf Int J Med Toxicol Drug Exp 29(10):875-887
48. Almenoff JS, DuMouchel W, Kindman LA, Yang X, Fram D (2003) Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol Drug Saf 12(6):517-521. doi:10.1002/pds.885
49. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11(1):3-10. doi:10.1002/pds.668
50. Gregoire F, Pariente A, Fourrier-Reglat A, Haramburu F, Begaud B, Moore N (2008) A signal of increased risk of hypoglycaemia with angiotensin receptor blockers caused by confounding. Br J Clin Pharmacol 66(1):142-145. doi:10.1111/j.1365-2125.2008.03176.x
51. Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, Begaud B (2003) Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 12(4):271-281
52. Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N (2007) Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf Int J Med Toxicol Drug Exp 30(10):891-898
53. Pariente A, Didailler M, Avillach P, Miremont-Salame G, Fourrier-Reglat A, Haramburu F, Moore N (2010) A potential competition bias in the detection of safety signals from spontaneous reporting databases. Pharmacoepidemiol Drug Saf 19(11):1166-1171. doi:10.1002/pds.2022
54. Pariente A, Daveluy A, Laribiere-Benard A, Miremont-Salame G, Begaud B, Moore N (2009) Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA. Drug Saf 32(5):441-447
55. Pariente A, Avillach P, Salvo F, Thiessard F, Miremont-Salame G, Fourrier-Reglat A, Haramburu F, Begaud B, Moore N (2012) Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France. Drug Saf 35(10):855-864. doi:10.2165/11631780-000000000- 00000
56. Coloma PM, Schuemie MJ, Trifiro G, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Giaquinto C, Corrao G, Pedersen L, van der Lei J, Sturkenboom M (2011) Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 20(1):1-11. doi:10.1002/pds.2053
57. Trifiro G, Patadia V, Schuemie MJ, Coloma PM, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Giaquinto C, Scotti L, Pedersen L, Avillach P, Sturkenboom MC, van der Lei J, Eu-Adr G (2011) EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection. Stud Health Technol Inform 166:25-30
58. Trifiro G, Fourrier-Reglat A, Sturkenboom MC, Diaz Acedo C, Van Der Lei J (2009) The EU-ADR project: preliminary results and perspective. Stud Health Technol Inform 148:43-49
59. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R (2011) Developing the Sentinel System-a national resource for evidence development. N Engl J Med 364(6):498-499. doi:10.1056/NEJMp1014427
60. Forrow S, Campion DM, Herrinton LJ, Nair VP, Robb MA, Wilson M, Platt R (2012) The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program. Pharmacoepidemiol Drug Saf 21[Suppl 1]:12-17. doi:10.1002/pds.2242
61. Platt R, Carnahan RM, Brown JS, Chrischilles E, Curtis LH, Hennessy S, Nelson JC, Racoosin JA, Robb M, Schneeweiss S, Toh S, Weiner MG (2012) The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf 21[Suppl 1]:1-8. doi:10.1002/pds.2343
62. Platt R, Wilson M, Chan KA, Benner JS, Marchibroda J, McClellan M (2009) The new Sentinel Network - improving the evidence of medical-product safety. N Engl J Med 361(7):645-647. doi:10.1056/NEJMp0905338
63. Dahabreh IJ, Sheldrick RC, Paulus JK, Chung M, Varvarigou V, Jafri H, Rassen JA, Trikalinos TA, Kitsios GD (2012) Do observational studies using propensity score methods agree with randomized trials? a systematic comparison of studies on acute coronary syndromes. Eur Heart J 33(15):1893-1901. doi:10.1093/eurheartj/ehs114
64. Gagne JJ, Fireman B, Ryan PB, Maclure M, Gerhard T, Toh S, Rassen JA, Nelson JC, Schneeweiss S (2012) Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf 21[Suppl 1]:32-40. doi:10.1002/pds.2316
65. Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S (2012) Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology 23(2):238-246. doi:10.1097/EDE. 0b013e3182459d7d
66. Rassen JA, Glynn RJ, Rothman KJ, Setoguchi S, Schneeweiss S (2012) Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiol Drug Saf 21(7):697-709. doi:10.1002/pds.2256
67. Rassen JA, Schneeweiss S (2012) Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiol Drug Saf 21[Suppl 1]:41-49. doi:10.1002/pds.2328
68. Garbe E, Kloss S, Suling M, Pigeot I, Schneeweiss S (2013) High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications. Eur J Clin Pharmacol 69(3):549-557. doi:10.1007/s00228-012-1334-2
69. Begaud B, Pere JC, Tubert P, Barat C, Haramburu F, Albin H (1987) Information centers on undesirable effects of drugs: also on alerting function. Therapie 42(2):231-237
70. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329(7456):15-19. doi:10.1136/bmj.329.7456.15
71. McLernon DJ, Bond CM, Hannaford PC, Watson MC, Lee AJ, Hazell L, Avery A (2010) Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals. Drug Saf Int J Med Toxicol Drug Exp 33(9):775-788. doi:10.2165/11536510-000000000-00000
72. van Hunsel F, Talsma A, van Puijenbroek E, de Jong-van den Berg L, van Grootheest K (2011) The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study. Pharmacoepidemiol Drug Saf 20(3):286-291. doi:10.1002/pds.2092
73. Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA, Abouelfath A, Gin H, Le Jeunne C, Pariente A, Droz C, Moore N (2012) Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 55(3):644-653. doi:10.1007/s00125-011-2429-5
74. Titier K, Girodet PO, Verdoux H, Molimard M, Begaud B, Haverkamp W, Lader M, Moore N (2005) Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Saf Int J Med Toxicol Drug Exp 28(1):35-51
75. Shah RR (2005) Drug-induced QT interval prolongation-regulatory guidance and perspectives on hERG channel studies. Novartis Found Symp 266:251-280, discussion 280-255
76. Haddad PM, Anderson IM (2002) Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62(11):1649-1671
77. Doig JC (1997) Drug-induced cardiac arrhythmias: incidence, prevention and management. Drug Saf Int J Med Toxicol Drug Exp 17(4):265-275
78. Campbell TJ (1990) Proarrhythmic actions of antiarrhythmic drugs: a review. Aust NZ J Med 20(3):275-282
79. Aldariz AE, Romero H, Baroni M, Baglivo H, Esper RJ (1986) QT prolongation and torsade de pointes ventricular tachycardia produced by Ketanserin. Pacing Clin Electrophysiol PACE 9(6 Pt 1):836-841
80. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ (2000) Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 85(1-2):169-182
81. Singh G (2000) Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther 7(2):115-121
82. Depont F, Fourrier A, Merliere Y, Droz C, Amouretti M, Begaud B, Benichou J, Moride Y, Velo GP, Sturkenboom M, Blin P, Moore N (2007) Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. Pharmacoepidemiol Drug Saf 16(8):891-900
83. Laharie D, Droz-Perroteau C, Benichou J, Amouretti M, Blin P, Begaud B, Guiard E, Dutoit S, Lamarque S, Moride Y, Depont F, Fourrier-Reglat A, Moore N (2010) Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users. Br J Clin Pharmacol 69(3):295-302. doi:10.1111/j.1365-2125.2009.03588.x
84. Moore N (2001) Comment on 'Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use ' Tramer et al., Pain 2000;85:169-182. Pain 91(3):401-402
85. Aronson JK, Barnett DB, Ferner RE, Ferro A, Henderson G, Maxwell SR, Rawlins MD, Webb DJ (2006) Poor prescribing is continual. BMJ 333(7571):756. doi:10.1136/bmj.333.7571.756-b
86. Weill A, Paita M, Tuppin P, Fagot JP, Neumann A, Simon D, Ricordeau P, Montastruc JL, Allemand H (2010) Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf 19(12):1256-1262. doi:10.1002/pds.2044
87. Claudia C, Claudia R, Agostino O, Simone M, Stefano G (2011) Minor head injury in warfarinized patients: indicators of risk for intracranial hemorrhage. J Trauma 70(4):906-909. doi:10.1097/TA.0b013e3182031ab7
88. Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Hillbom M (2011) Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke J Cereb Circ 42(9):2431-2435. doi:10.1161/STROKEAHA.111.615260
89. Subherwal S, Peterson ED, Chen AY, Roe MT, Washam JB, Gage BF, Bach RG, Bhatt DL, Wiviott SD, Lopes RD, Alexander KP, Wang TY (2012) Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry. Circulation 125(11):1414-1423. doi:10.1161/CIRCULATIONAHA.111.059188
90. Lacoste-Roussillon C, Pouyanne P, Haramburu F, Miremont G, Begaud B (2001) Incidence of serious adverse drug reactions in general practice: a prospective study. Clin Pharmacol Ther 69(6):458-462
91. Pouyanne P, Haramburu F, Imbs JL, Begaud B (2000) Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ 320(7241):1036
92. Pariente A, Dartigues JF, Benichou J, Letenneur L, Moore N, Fourrier-Reglat A (2008) Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging 25(1):61-70
93. Lagnaoui R, Depont F, Fourrier A, Abouelfath A, Begaud B, Verdoux H, Moore N (2004) Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 60:523-529
94. Theophile H, Miremont-Salame G, Robinson P, Moore N, Begaud B, Haramburu F (2011) Relevance of a "Dear Doctor letter" to alert healthcare providers to new recommendations for vitamin D administration. Eur J Clin Pharmacol 67(7):681-686. doi:10.1007/s00228-011-1055-y
95. Ruiter R, Visser LE, van Herk-Sukel MP, Geelhoed-Duijvestijn PH, de Bie S, Straus SM, Mol PG, Romio SA, Herings RM, Stricker BH (2012) Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008. Drug Saf Int J Med Toxicol Drug Exp 35(6):471-480. doi:10.2165/11596950-000000000-00000
96. Piening S, Reber KC, Wieringa JE, Straus SM, de Graeff PA, Haaijer-Ruskamp FM, Mol PG (2012) Impact of safety-related regulatory action on drug use in ambulatory care in the Netherlands. Clin Pharmacol Ther 91(5):838-845. doi:10.1038/clpt.2011.308
97. Piening S, Haaijer-Ruskamp FM, de Vries JT, van der Elst ME, de Graeff PA, Straus SM, Mol PG (2012) Impact of safety-related regulatory action on clinical practice: a systematic review. Drug Saf Int J Med Toxicol Drug Exp 35(5):373-385. doi:10.2165/11599100-000000000-00000
98. Piening S, Haaijer-Ruskamp FM, de Graeff PA, Straus SM, Mol PG (2012) Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands. Drug Saf Int J Med Toxicol Drug Exp 35(11):1061-1072. doi:10.2165/11635750-000000000-00000
99. Bahri P, Mol PG, Theophile H, Edwards IR, Hugman BP (2011) Communication in drug safety: a report from an interactive debate held at the 10th annual meeting of the international society of pharmacovigilance (ISoP), 2010. Drug Saf Int J Med Toxicol Drug Exp 34(10):881-882. doi:10.2165/11594430-000000000-00000
100. Mol PG, Straus SM, Piening S, de Vries JT, de Graeff PA, Haaijer-Ruskamp FM (2010) A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009. Drug Saf Int J Med Toxicol Drug Exp 33(6):463-474. doi:10.2165/11532840-000000000-00000
101. Einarson TR (1993) Drug-related hospital admissions. Ann Pharmacother 27(7-8):832-840
102. Moore N, Lecointre D, Noblet C, Mabille M (1998) Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 45(3):301-308
103. Birkett D, Brosen K, Cascorbi I, Gustafsson LL, Maxwell S, Rago L, Rawlins M, Reidenberg M, Sjoqvist F, Smith T, Thuerman P, Walubo A, Orme M, Sjoqvist F (2010) Clinical pharmacology in research, teaching and health care: considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol 107(1):531-559. doi:10.1111/j.1742- 7843.2010.00602.x
104. Orme MC (2003) Clinical pharmacology education in Europe: undergraduate through postgraduate to continuing professional development. Am J Ther 10(6):462-464
105. Jaillon P (2006) Teaching basic and clinical pharmacology to medical students: a 2006 survey in French schools of medicine. Therapie 61(5):439-446
106. Maxwell SR, Cascorbi I, Orme M, Webb DJ (2007) Educating European (junior) doctors for safe prescribing. Basic Clin Pharmacol Toxicol 101(6):395-400. doi:10.1111/j.1742-7843.2007.00141.x
107. Heaton A, Webb DJ, Maxwell SR (2008) Undergraduate preparation for prescribing: the views of 2413 UK medical students and recent graduates. Br J Clin Pharmacol 66(1):128-134. doi:10.1111/j.1365-2125.2008.03197.x
108. Sandilands EA, Reid K, Shaw L, Bateman DN, Webb DJ, Dhaun N, Kluth DC (2011) Impact of a focussed teaching programme on practical prescribing skills among final year medical students. Br J Clin Pharmacol 71(1):29-33. doi:10.1111/j.1365-2125.2010.03808.x
109. Duncan EM, Francis JJ, Johnston M, Davey P, Maxwell S, McKay GA, McLay J, Ross S, Ryan C, Webb DJ, Bond C (2012) Learning curves, taking instructions, and patient safety: using a theoretical domains framework in an interview study to investigate prescribing errors among trainee doctors. Implement Sci IS 7(1):86. doi:10.1186/1748-5908-7-86
110. Ross S, Ryan C, Duncan EM, Francis JJ, Johnston M, Ker JS, Lee AJ, Macleod MJ, Maxwell S, McKay G, McLay J, Webb DJ, Bond C (2013) Perceived causes of prescribing errors by junior doctors in hospital inpatients: a study from the PROTECT programme. BMJ Qual Saf 22(2):97-102. doi:10.1136/bmjqs-2012-001175
111. Clark RC, Maxwell SR, Kerr S, Cuthbert M, Buchanan D, Steinke D, Webb DJ, Bateman ND (2007) The influence of primary care prescribing rates for new drugs on spontaneous reporting of adverse drug reactions. Drug Saf Int J Med Toxicol Drug Exp 30(4):357-366
112. Moore N (2005) Assessing drug safety. BMJ 330(7490):539-540
113. Blazejewski S, Girodet PO, Orriols L, Capelli A, Moore N, Cesir Group FT (2012) Factors associated with serious traffic crashes: a prospective study in Southwest France. JAMA Int Med (formerly Arch Intern Med) 172, no. 13. doi:10.1001/archinternmed.2012.1695
114. Hamberg AK, Friberg LE, Hanseus K, Ekman-Joelsson BM, Sunnegardh J, Jonzon A, Lundell B, Jonsson EN, Wadelius M (2013) Warfarin dose prediction in children using pharmacometric bridging-comparison with published pharmacogenetic dosing algorithms. Eur J Clin Pharmacol. doi:10.1007/s00228-012-1466-4
115. Hamberg AK, Wadelius M, Lindh JD, Dahl ML, Padrini R, Deloukas P, Rane A, Jonsson EN (2010) A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin Pharmacol Ther 87(6):727-734. doi:10.1038/clpt.2010.37
116. Pirmohamed M (2012) Genetics and the potential for predictive tests in adverse drug reactions. Chem Immunol Allergy 97:18-31. doi:10.1159/000335613
117. Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA (2011) Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 127[Suppl 3]:S60-S66. doi:10.1016/j.jaci.2010.11.046